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Mr G.B. presented to casualty with bilateral 
weakness in distal lower limbs which was 
progressive. He had a history of gastrointestinal 
illness with severe diarrhoea. On examination 
he had decreased deep tendon reflexes (ankle 
jerk) and an unsteady gait. A lumbar puncture 
was done and the findings were unremarkable. 
An EMG was also done and confirmed 
Guillain-Barré Syndrome. He was treated with 
intravenous immunoglobulin and physiotherapy 
and he is currently still in hospital recovering 
well. 
Fact file on Guillain-Barré Syndrome:
Guillain-Barré Syndrome (GBS) is a neurological 
disorder characterised by weakness, most 
prominently in the distal extremities at first 
and which progresses proximally. Absent 
or decreased myotactic reflexes are also an 
important feature of this syndrome (Walling 
& Dickson, 2013).  It was first described 
by Guillain, Barré and Strohl, back in 1916 
(Guillain et al, 1916).  GBS is a rare condition 
with incidence estimated at 1.1/100,000/
year – 1.8/100,000/year. The incidence also 
increases with age; over 50 years incidence is 
between 1.7/100,000/year – 3.3/100,000/year 
(McGrogan et al, 2009). Sejvar et al also noticed 
that males have a higher tendency to develop 
GBS; the ratio is 3:2 (Sejvar et al, 2013). Some 
complications of this disorder include breathing 
difficulties due to weakness or paralysis of the 
respiratory muscles, blood clots and pressure 
sores due to immobility, cardiac arrhythmias, 
dysphagia and also relapse (Alshekhlee et al, 
2008). 
Some criteria that must be present for GBS 
diagnosis are: bilateral symptoms, reduced 
myotactic reflexes and weakness with 
decreased or absent reflexes. Moreover, 
there can be autonomic and cranial nerve 
involvement and some sensory disturbances. 
Cerebrospinal fluids obtained through lumbar 
puncture usually reveal a high protein content 
in the fluid but normal amount of white blood 
cells (Walling & Dickson, 2013). 
GBS have 5 subtypes. The most common 
is acute inflammatory demyelinating 
polyradiculoneuropathy (AIDP) with 
demyelination of peripheral nerves causing a 
symmetrical weakness, hyporeflexia or areflexia. 
Acute motor axonal neuropathy (AMAN) is 
another subtype characterised by antibodies 
targeting different gangliosides such as GM1 
and GD1a. This subtype only presents with 
motor symptoms unlike another subtype 
called acute motor-sensory axonal neuropathy, 
having both motor and sensory involvement. 
Miller Fisher syndrome and acute autonomic 
neuropathy are the rare subtypes of GBS 
(Walling & Dickson, 2013).
A study done by Hadden et al, discovered 
that some infections, particularly caused be 
Campylobacter jejuni, Cytomegalovirus and 
Epstein-Barr virus, could be the cause of some 
developments of GBS (Hadden et al, 2001). 
In fact the majority of patient present with a 
history of gastrointestinal symptoms, fever, a 
cough, sore throat etc. This link is explained by 
the fact that GBS is an inflammatory neuropathy. 
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C.jejuni was found to express antigens similar to 
gangliosides. So due to molecular mimicry and 
a cross-reactivity, antibodies start targeting the 
infectious agent as well as the gangliosides. In 
AIDP, the antibodies target the myelin whereas 
in AMAN the nodes of Ranvier are damaged 
(van Doorn et al, 2008). Some have also 
suggested that following certain vaccinations 
such as influenza, tetanus and hepatitis, one 
can also have a higher risk of developing GBS 
but this is very rare and the benefits outweigh 
the risks (De Wals, 2012). Recently an upsurge 
of GBS was linked to the Zika virus epidemic 
(Wahid et al, 2016). 
Treatment of patients with GBS includes plasma 
exchange to eliminate circulating immune 
complexes or intravenous immune globulin 
therapy. Most patients recover however about 
3% still die regardless of therapy (Walling & 
Dickson, 2013).
Case report on Guillain-Barré Syndrome 
Presenting complaint: 
A 32 year old man presented to casualty with 
decreased power in both his distal lower limbs 
after abruptly falling while walking on the 
pavement. Mr G.B has also decreased sensation 
on both lower limbs and the weakness is 
progressing proximally. 
History of presenting complaint: 
4 weeks previous to the incident he 
experienced diarrhoea, fever, chills and 
sweating. The diarrhoea was sometimes with 
mucus but without blood and brown in colour. 
He says he was having diarrhoea about 20 times 
a day. He also complained of dull hypogastric 
pain before an onset of diarrhoea. The pain did 
not radiate to anywhere else and stopped when 
Mr G.B did not have any more episodes of 
diarrhoea. He did not experience any vomiting. 
He noticed about 7kg weight loss in the past 
month with a loss for appetite. 1 week before 
the incident he noticed his hand cramping and 
also diminished movement in his legs. He also 
mentioned that he hobbled a bit before the 
collapse and complained of different sensation 
on both his knees. Mr G.B did not have any 
shortness of breath nor swallowing difficulties. 
He did not have vision problems, headaches or 
any other pain.
Previous medical/surgical history: 
Mr G.B. had a fracture in his hand and was 
treated with a metal plate. He does not suffer 
from diabetes, hypertension, liver or kidney 
problems, high cholesterol
Drug history: 
Mr G.B. does not take any drugs and he does 
not have any drug or food allergies. 
Family history: 
His father suffers from Type 1 Diabetes and 
raised blood pressure which is controlled.
Social history: 
Mr G.B. consumes 2 pints of beer a day. He 
does not smoke nor consumes recreational 
drugs. He lives with his girlfriend in an 
apartment. He works as an operations manager 
in finance. 
Systemic enquiry: 
Nil to note
Physical examinations and Preliminary 
investigations:
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Differential diagnosis:
• Guillain-Barré Syndrome
• Chronic inflammatory demyelinating 
polyneuropathy
Diagnostic investigations:
• Requested investigation: Lumbar Puncture 
• Justification for procedure: To obtain CSF 
composition
• Result and conclusion: No cells or bacteria 
seen. The findings are unremarkable
• Requested investigation: Nerve conduction 
studies and Electromyography
• Justification for procedure: To confirm 
neuropathy and identify the extent, severity 
and whether the syndrome is demyelinating 
or axonal.
• Result and conclusion: This study shows a 
predominantly demyelinating patchy motor 
polyneuropathy. The findings in keeping 
with GBS in the appropriate clinical setting
Diagnosis:
The symptoms were suggestive of GBS. Mr 
G.B. had distal weakness in his lower limbs 
with progression to proximal muscle. He also 
had decreased ankle jerk reflexes. This agreed 
with the GBS diagnosis. On investigation the 
cerebrospinal fluid did not have any elevated 
protein which was not in keeping with GBS, 
although his white blood cell count was 
normal. Diagnosis of GBS was finalised with 
EMG showing a demyelinating patchy motor 
polyneuropathy.
Management:
• Immunoglobulin therapy: Intravenous 
immunoglobulin 0.4g/kg body weight per 
day were given for 5 days
• Physiotherapy: the patient started getting 
out of bed with assistance and started 
regaining power in his lower limb muscles. 
Mr. G.B. is not experiencing any disability 
now however he has some mild symptoms 
(1 in the Modified Rankin Scale). He goes 
about his normal activities without any help. 
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